
Didier Leroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5073921/publications.pdf Version: 2024-02-01



DIDIED LEDON

#	Article	IF	CITATIONS
1	Transmission-blocking drugs for malaria elimination. Trends in Parasitology, 2022, 38, 390-403.	3.3	30
2	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance. Science Translational Medicine, 2021, 13, .	12.4	25
3	Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends in Parasitology, 2021, 37, 709-721.	3.3	53
4	Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Reports Medicine, 2021, 2, 100423.	6.5	19
5	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
6	Fueling Open Innovation for Malaria Transmission-Blocking Drugs: Hundreds of Molecules Targeting Early Parasite Mosquito Stages. Frontiers in Microbiology, 2019, 10, 2134.	3.5	31
7	African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malaria Journal, 2019, 18, 126.	2.3	22
8	Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase. Science Translational Medicine, 2017, 9, .	12.4	204
9	How to tackle antimalarial resistance?. EMBO Molecular Medicine, 2017, 9, 133-134.	6.9	9
10	Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nature Medicine, 2017, 23, 917-928.	30.7	384
11	Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission. Scientific Reports, 2017, 7, 17680.	3.3	22
12	A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Medicine, 2017, 15, 181.	5.5	49
13	Discovering New Transmission-Blocking Antimalarial Compounds: Challenges and Opportunities. Trends in Parasitology, 2016, 32, 669-681.	3.3	40
14	A chemical susceptibility profile of the <i>Plasmodium falciparum</i> transmission stages by complementary cell-based gametocyte assays. Journal of Antimicrobial Chemotherapy, 2016, 71, 1148-1158.	3.0	37
15	High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host and Microbe, 2016, 19, 114-126.	11.0	140
16	Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malaria Journal, 2015, 14, 213.	2.3	85
17	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	27.8	353
18	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Science Translational Medicine, 2015, 7, 296ra111.	12.4	254

DIDIER LEROY

#	Article	IF	CITATIONS
19	Defining the biology component of the drug discovery strategy for malaria eradication. Trends in Parasitology, 2014, 30, 478-490.	3.3	41
20	The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites. PLoS Medicine, 2012, 9, e1001169.	8.4	301
21	Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence "Transmission Blocking―Assay. PLoS ONE, 2012, 7, e35019.	2.5	126